Abstract

An open prospective randomized 16-week study was conducted to study the effect of the drug Nicomex as part of combination therapy in patients with CHF and type 2 diabetes on structural and functional parameters of the liver. The hepatoprotective capabilities of the drug Nicomex have been demonstrated: a significant decrease in the severity of cytolysis, cholestasis, steatosis index, the ability to reduce the severity of structural changes in the liver according to ultrasound. The noted hepatoprotective effects are mediated by the effect of the drug Nicomex on the processes of lipid peroxidation, the activity of antioxidant defense enzymes, and a decrease in the manifestation of chronic systemic inflammation. The use of the drug Nicomex contributes to a more pronounced combined hypolipidemic effect, and also reduces the severity of insulin resistance. The noted hepatoprotective effects of the drug Nicomex improve not only metabolic processes in the liver, but also can significantly change the cardiovascular risk in this category of patients.